Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms

被引：0
|
作者：
Rui-Xia Xu
Jun Liu
Xiao-Lin Li
Sha Li
Yan Zhang
Yan-Jun Jia
Jing Sun
Jian-Jun Li
机构：
[1] FuWai Hospital,Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease
[2] National Center for Cardiovascular Disease,undefined
[3] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Translational Medicine | / 13卷
关键词：
Ezetimibe; PCSK9; Liver; Intestine; Kidney; Molecular mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms
    Xu, Rui-Xia
    Liu, Jun
    Li, Xiao-Lin
    Li, Sha
    Zhang, Yan
    Jia, Yan-Jun
    Sun, Jing
    Li, Jian-Jun
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [2] The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe
    Fazio, Sergio
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 17 : 23 - 26
  • [3] A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice
    Essalmani, Rachid
    Weider, Elodie
    Marcinkiewicz, Jadwiga
    Chamberland, Ann
    Susan-Resiga, Delia
    Roubtsova, Anna
    Seidah, Nabil G.
    Prat, Annik
    BIOLOGICAL CHEMISTRY, 2018, 399 (12) : 1363 - 1374
  • [4] Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid-lowering therapy
    Wojcik, Cezary
    REVIEWS IN HEALTH CARE, 2016, 7 (01) : 17 - 25
  • [5] Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings
    Muntner, Paul
    Ghazi, Lama
    Jones, Jenna
    Dhalwani, Nafeesa
    Poudel, Bharat
    Wen, Ying
    Chen, Ligong
    Wang, Zhixin
    Bittner, Vera
    Kalich, Bethany
    Farkouh, Michael E.
    Woodward, Mark
    Colantonio, Lisandro D.
    Rosenson, Robert S.
    ADVANCES IN THERAPY, 2024, 41 (06) : 2399 - 2413
  • [6] PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials
    Benhuri, Benjamin
    Ueyama, Hiroki
    Takagi, Hisato
    Briasoulis, Alexandros
    Kuno, Toshiki
    CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (04) : 390 - 397
  • [7] The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina
    Zhang, Jian
    Long, Mingzhi
    Yu, Yichao
    JOURNAL OF THORACIC DISEASE, 2017, 9 (05) : 1226 - 1233
  • [8] Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study
    Toru Miyoshi
    Keigo Nakamura
    Masayuki Doi
    Hiroshi Ito
    American Journal of Cardiovascular Drugs, 2015, 15 : 213 - 219
  • [9] Diabetes alters LDL receptor and PCSK9 expression in rat liver
    Niesen, Melissa
    Bedi, Mohini
    Lopez, Dayami
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2008, 470 (02) : 111 - 115
  • [10] Inhibition of squalene synthase upregulates PCSK9 expression in rat liver
    Bedi, Mohini
    Niesen, Melissa
    Lopez, Dayami
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2008, 470 (02) : 116 - 119
12345